While we can predict the drug sensitivity of the majority of cancer‐associated EGFR variants, there are less common EGFR variants 16, 17, 18, 19, 20, 21, 22, 23, 24 that remain poorly characterized, and thus, their clinical relevance remains unclear. This evidence concerns the gene EGFR and cancer.